Literature DB >> 22317908

HIV-1 mother-to-child transmission and drug resistance among Brazilian pregnant women with high access to diagnosis and prophylactic measures.

Keila Correia Alcântara1, Janaína Bacelar Accioli Lins, Maly Albuquerque, Letícia Mara Aires, Ludimila Paula Vaz Cardoso, Ana Lúcia Minuzzi, Mariane Martins Araújo Stefani.   

Abstract

BACKGROUND: A high-coverage public health prenatal program (70,000 women/year) from central western Brazil/Goias State has represented a unique opportunity for the early diagnosis of HIV-1 and implementation of strategies to prevent mother-to-child transmission (MTCT).
OBJECTIVES: To investigate MTCT among a prospective cohort of HIV-1 infected mothers/exposed infants. STUDY
DESIGN: 142 mothers/their 149 infants (2008-2010) were investigated regarding maternal viral load, CD4(+)cell counts, HIV-1 pol sequences; infants' HIV-1 RNA tests (30/120 days), sequential anti-HIV-1/2 serology. HIV-1 subtypes were assigned by REGA. Transmitted drug resistance was identified by the Calibrated Population Resistance tool, secondary resistance by Stanford HIV-1 Drug Resistance/International AIDS Society databases.
RESULTS: Mothers (median age=24 years; 25/142 adolescents) were diagnosed during prenatal care (2008-2010) or previously (1994-2007). Recent cases were younger, mostly asymptomatic. Undetectable viremia and MTCT prophylaxis predominated in formerly diagnosed mothers. Recent cases had higher subtype C prevalence. One naive patient had transmitted resistance; ten antiretroviral-experienced patients had secondary resistance: 6 from MTCT prophylaxis, 4 under HAART. Late disclosure of diagnosis, vaginal delivery, breastfeeding, lack of oral zidovudine were observed in the three MTCT cases (3/149; 2.01%). Two of three infected infants harbored subtype C; infected infants/mothers did not have drug resistance mutations. Two of the transmitting-mothers had viremia <1000 copies/ml. Among exposed-uninfected infants the median time to seroreversion was 12 months.
CONCLUSIONS: In this study delayed disclosure of diagnosis, partial/no preventive measures, drug resistance among asymptomatic women under prophylaxis and MTCT in low viremic mothers raise concerns. The expansion of subtype C infection corroborates surveillance of HIV-1 diversity in this region.
Copyright © 2012 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22317908     DOI: 10.1016/j.jcv.2012.01.011

Source DB:  PubMed          Journal:  J Clin Virol        ISSN: 1386-6532            Impact factor:   3.168


  14 in total

1.  Transmitted HIV resistance among pregnant young women infected with HIV-1 in Brazil.

Authors:  Zelma Bernades da Costa; Yanna Andressa Ramos de Lima; Celina Maria Turchi Martelli; Mariane Martins de Araújo Stefani
Journal:  AIDS Patient Care STDS       Date:  2013-08       Impact factor: 5.078

2.  Analysis of primary resistance mutations to HIV-1 entry inhibitors in therapy naive subtype C HIV-1 infected mother-infant pairs from Zambia.

Authors:  Hongyan Guo; Chang Liu; Bin Liu; Charles Wood; Xiaohong Kong
Journal:  J Clin Virol       Date:  2013-06-25       Impact factor: 3.168

3.  Low rate of transmitted drug resistance may indicate low access to antiretroviral treatment in Maranhão State, northeast Brazil.

Authors:  Maria Edileuza Soares Moura; Mônica Nogueira da Guarda Reis; Yanna Andressa Ramos Lima; Kelsen Dantas Eulálio; Ludimila Paula Vaz Cardoso; Mariane Martins de Araújo Stefani
Journal:  AIDS Res Hum Retroviruses       Date:  2014-11-20       Impact factor: 2.205

4.  Comparative analysis of the fusion efficiency elicited by the envelope glycoprotein V1-V5 regions derived from human immunodeficiency virus type 1 transmitted perinatally.

Authors:  Hongyan Guo; Levon G Abrahamyan; Chang Liu; Mackenzie Waltke; Yunqi Geng; Qimin Chen; Charles Wood; Xiaohong Kong
Journal:  J Gen Virol       Date:  2012-09-05       Impact factor: 3.891

5.  Viraemia before, during and after pregnancy in HIV-infected women on antiretroviral therapy in rural KwaZulu-Natal, South Africa, 2010-2015.

Authors:  Terusha Chetty; Marie-Louise Newell; Claire Thorne; Anna Coutsoudis
Journal:  Trop Med Int Health       Date:  2017-11-28       Impact factor: 3.918

6.  Prenatal testing and prevalence of HIV infection during pregnancy: data from the "Birth in Brazil" study, a national hospital-based study.

Authors:  Rosa Maria Soares Madeira Domingues; Celia Landmann Szwarcwald; Paulo Roberto Borges Souza; Maria do Carmo Leal
Journal:  BMC Infect Dis       Date:  2015-02-26       Impact factor: 3.090

7.  Prenatal Transmission of Syphilis and Human Immunodeficiency Virus in Brazil: Achieving Regional Targets for Elimination.

Authors:  Rodrigo Cerda; Freddy Perez; Rosa Maria S M Domingues; Paula M Luz; Beatriz Grinsztejn; Valdilea G Veloso; Sonja Caffe; Jordan A Francke; Kenneth A Freedberg; Andrea L Ciaranello
Journal:  Open Forum Infect Dis       Date:  2015-05-22       Impact factor: 3.835

8.  Quality of life of men with AIDS and the model of social determinants of health.

Authors:  Gilmara Holanda da Cunha; Maria Luciana Teles Fiuza; Elucir Gir; Priscila de Souza Aquino; Ana Karina Bezerra Pinheiro; Marli Teresinha Gimeniz Galvão
Journal:  Rev Lat Am Enfermagem       Date:  2015 Feb-Apr

9.  Variability of HIV-1 genomes among children and adolescents from São Paulo, Brazil.

Authors:  Sabri Saeed Sanabani; Rodrigo Pessôa; Ana Carolina Soares de Oliveira; Vanessa Pouza Martinez; Maria Teresa Maidana Giret; Regina Célia de Menezes Succi; Karina Carvalho; Claudia Satiko Tomiyama; Douglas F Nixon; Ester Cerdeira Sabino; Esper Georges Kallas
Journal:  PLoS One       Date:  2013-05-07       Impact factor: 3.240

10.  Tracing the origin and northward dissemination dynamics of HIV-1 subtype C in Brazil.

Authors:  Edson Delatorre; José C Couto-Fernandez; Monick Lindenmayer Guimarães; Ludimila Paula Vaz Cardoso; Keila Correia de Alcantara; Mariane Martins de Araújo Stefani; Hector Romero; Caio C M Freire; Atila Iamarino; Paolo M de A Zanotto; Mariza G Morgado; Gonzalo Bello
Journal:  PLoS One       Date:  2013-09-12       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.